DATAMEDRIX GMBH

Their core work

DATAMEDRIX GMBH is a Vienna-based biomedical SME operating at the intersection of structural biology and molecular diagnostics. Their work spans protein structural analysis of disease-related targets — specifically tau aggregation in Alzheimer's pathology — and the development of nucleic acid-based diagnostic platforms for cancer detection via liquid biopsy. In practice, they contribute specialist analytical expertise to international research consortia, bringing capabilities in NMR spectroscopy, cryo-EM, and RNA profiling technologies. Their commercial angle appears to be translating fundamental biomarker research into applied diagnostic tools for clinical use.

What they specialise in

How they've shifted over time

In their earliest H2020 participation, DATAMEDRIX focused on the structural biology end of disease research — tau protein conformation, NMR-based characterization, and cryo-EM imaging within the context of neurodegenerative disease. By their second project (2021), the focus shifted decisively toward applied molecular diagnostics: liquid biopsy, RNA circulating biomarkers, and cancer detection platforms. This is a meaningful pivot from understanding disease mechanisms at the protein level to building tools that detect disease in patient samples — moving upstream in the clinical translation chain.

DATAMEDRIX is moving toward applied clinical diagnostics — specifically nucleic acid detection platforms for oncology — which suggests future collaborations are most likely to involve cancer early detection, liquid biopsy standardization, or point-of-care RNA sensor development.

How they like to work

DATAMEDRIX has participated exclusively as a consortium partner across both projects — never as a coordinator — indicating they prefer to contribute specialist expertise within larger research networks rather than lead project management. Both projects are MSCA-RISE exchanges, which typically involve large multi-institutional consortia designed for researcher mobility, and indeed their 22 partners across 13 countries from just 2 projects confirms broad network exposure. This pattern suggests they are a reliable specialist node: they bring focused technical capability and participate actively, but are not currently positioned as a project-driving organization.

Despite only two projects, DATAMEDRIX has built contact with 22 unique partners spanning 13 countries — an unusually broad reach for a micro-SME, driven by the inherently international structure of MSCA-RISE consortia. Their network spans European research institutions and likely includes universities and clinical research centers across multiple EU member states.

What sets them apart

DATAMEDRIX occupies a rare niche as a private SME within MSCA research exchange programs, which are predominantly populated by universities and public research institutes — their commercial orientation likely means they bring an application-readiness perspective that pure academic partners cannot. Their dual expertise bridging protein structural biology (NMR, cryo-EM) and nucleic acid diagnostics (liquid biopsy, miRNA, PNA) is an uncommon combination, making them useful to consortia that need to span mechanistic research and diagnostic translation. For a consortium builder, they represent a compact specialist partner who can cover both upstream target biology and downstream detection platform development.

Highlights from their portfolio

• diaRNAgnosis
  The higher-funded and more applied of the two projects, it targets a commercially significant problem — non-invasive cancer detection via cell-free RNA — using a novel sensor platform approach that sits close to clinical translation.
• InterTAU
  Positions DATAMEDRIX within Alzheimer's structural biology research, a high-profile therapeutic area, and demonstrates their capacity to contribute advanced imaging and spectroscopy methods (cryo-EM, solid-state NMR) to international consortia.